ArticleAmerican journal of preventive cardiology2026

Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.

Luke Laffin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.